Blueprint Medicines Corporation (BPMC)
Jul 18, 2025 - BPMC was delisted (reason: acquired by SNY)
129.46
0.00 (0.00%)
Inactive · Last trade price on Jul 17, 2025
Blueprint Medicines Revenue
Blueprint Medicines had revenue of $149.41M in the quarter ending March 31, 2025, with 55.45% growth. This brings the company's revenue in the last twelve months to $562.12M, up 99.19% year-over-year. In the year 2024, Blueprint Medicines had annual revenue of $508.82M with 104.04% growth.
Revenue (ttm)
$562.12M
Revenue Growth
+99.19%
P/S Ratio
n/a
Revenue / Employee
$820,615
Employees
649
Market Cap
n/a
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 508.82M | 259.44M | 104.04% |
| Dec 31, 2023 | 249.38M | 45.34M | 22.22% |
| Dec 31, 2022 | 204.04M | 23.96M | 13.30% |
| Dec 31, 2021 | 180.08M | -613.66M | -77.31% |
| Dec 31, 2020 | 793.74M | 727.22M | 1,093.37% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionBPMC News
- 5 months ago - BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC - Business Wire
- 6 months ago - Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses - PRNewsWire
- 6 months ago - Johnson Fistel Investigates Fairness of Proposed Sale of Blueprint Medicines - GlobeNewsWire
- 6 months ago - Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. - Barrons
- 6 months ago - Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology - PRNewsWire
- 6 months ago - Sanofi buys US biopharma group Blueprint in $9.1 bln deal - Reuters
- 6 months ago - Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion - WSJ
- 6 months ago - Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology - GlobeNewsWire